View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 17, 2022

MediciNova enters deal to take part in long Covid treatment trial

The trial of MN-166 will commence following regulatory review and finalisation of the protocol.

MediciNova has entered an agreement to partner with the University Health Network to take part in a clinical trial of MN-166 (ibudilast) and other therapies to treat long Covid.

Named Recovering from Covid-19 Lingering Symptoms Adaptive Integrative Medicine Trial (RECLAIM), the multicentre, randomised, grant-funded trial will analyse MN-166.

Canada-based academic health sciences centre University Health Network has the largest hospital-based research programme in the country. 

The Canadian government is providing funds for the trial through the Canadian Institutes of Health Research.  

The trial will commence following regulatory review and finalisation of the protocol.

A small molecule compound, MN-166 (ibudilast) hinders phosphodiesterase type-4 and inflammatory cytokines such as macrophage migration inhibitory factor.

It is currently being analysed in late-stage clinical trials to treat neurodegenerative ailments including amyotrophic lateral sclerosis, progressive multiple sclerosis, and degenerative cervical myelopathy, as well as glioblastoma, chemotherapy-induced peripheral neuropathy, and substance use disorder. 

The compound is also being assessed in people who are at risk of developing acute respiratory distress syndrome.  

MediciNova chief medical officer Kazuko Matsuda said: “We are excited to collaborate with Dr Cheung and the University Health Network on this large, grant-funded study to explore the potential of MN-166 in long Covid. 

“There is a large unmet medical need for patients with this disorder, which can have serious ramifications on quality of life, health care utilisation, and ability to return to work.”

A clinical-stage biopharma firm, MediciNova focuses on the development of wide-ranging, late-stage pipeline, new small molecule treatments for inflammatory, fibrotic, and neurodegenerative ailments. 

The company currently has 11 programmes in clinics, which are based on MN-166 and MN-001 (tipelukast).

In July this year, MediciNova began a Phase II trial of MN-001 for treating non-alcoholic fatty liver disease patients with type 2 diabetes, mellitus, and hypertriglyceridemia.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena